AbbVie is betting more than $1.9 billion on a French biotech’s long-acting injectable technology.
The deal gives Medincell $35 million upfront and up to $1.9 billion in milestones for the development of up to six therapeutic long-acting products. Medincell said on Tuesday the work will span “multiple therapeutic areas and indications,” but declined to go into further detail. AbbVie also declined to comment on its therapeutic focus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.